Where does Galecto Biotech AB rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Galecto Biotech AB ranks #12,940 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Galecto Biotech AB hold?

Galecto Biotech AB holds 23 US utility patents granted between 2016 and 2025, spanning 6 technology areas.

What is Galecto Biotech AB's Innovation Score?

Galecto Biotech AB has an Innovation Score of 32.6 out of 100 (42nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Galecto Biotech AB focus on?

Galecto Biotech AB's top technology area is C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids) with 22 patents, ranking #27 of 896 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Galecto Biotech AB's patent grant rate increasing or decreasing?

Galecto Biotech AB's recent grant velocity is +75% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Galecto Biotech AB's patents?

Galecto Biotech AB's patents average 16.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Galecto Biotech AB patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Galecto Biotech AB

USPTO PatentsView assignee record - 23 granted patents across 6 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Galecto ranks #12,940 of 49,997 tracked US assignees by granted-patent volume, with 23 patents across 6 technology areas.

#12,940
of 49,997 US assignees by volume: 42nd percentile
by Innovation Score (32.6/100): 16.1
avg claims per patent: +75%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R12940 · Foreign Corporation #12,940 · 23 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 23 grants
MID-PACK #12,940/49,997
PHOTO-FINISH Frogparking
CPC-NARROW C07H · 6 areas
INNOV-THIN 32.6/100
CLAIMS-RICH 16.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +75% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Frogparking Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Galecto’s 32.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.0 pts (34%) Velocity 3.3 pts (10%) Breadth 8.7 pts (27%) Claim depth 9.7 pts (30%)

Qualcomm Incorporated · highest

85
Galecto Biotech AB · this assignee

33
3D Lighting… · lowest

7

What this shows Galecto's Innovation Score is 32.6/100 (42nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Galecto?

Each dot is one of Galecto’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Galecto’s own 16.1 claims/patent is ABOVE the 10.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Galecto vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Galecto's grants concentrate

Galecto Biotech AB is a focused PatentsView assignee: 6 CPC subclasses with 95.7% of grants classified under C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids). Peak complete grant year is 2020 (5 grants) versus a trough of 1 in 2023. By volume, Galecto sits between Frogparking Limited and Giantplus Technology Co., Ltd..

Galecto's three-year grant acceleration

Galecto Biotech AB shows 6 grants in 2022–2024 against only 12 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Frogparking

23
Fujikoshi Machine…

23
Fulian Yuzhan Pre…

23
G3 Enterprises

23
Gelest

23
Genius

23
Genmont Biotech I…

23
Giantplus Technol…

23
Galecto Biotech AB ◀

23

What this shows Galecto holds 23 patents at rank #12,938, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Galecto

By rank, the assignees closest to #12,938 in granted patent volume.

Leaders in C07H (Sugars)

Other assignees with the most granted patents in Galecto's primary technology class.

Galecto's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

33 42nd percentile higher than 42% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Galecto Biotech AB patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	8.7%
2017	2	8.7%
2019	4	17.4%
2020	5	21.7%
2021	3	13.0%
2022	3	13.0%
2023	1	4.3%
2024	2	8.7%
2025partial year	1	4.3%

Which technologies does Galecto Biotech AB patent most?

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 22

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 20

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 14

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 3

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Galecto Biotech AB's patent record in context - here's where to go next.

Galecto Biotech AB's lead technology class is C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids), 95.7% of its portfolio - see every assignee active in that class. Explore C07H
Ranked #12,940 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Galecto Biotech AB against Frogparking Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.